-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Treatment of VTE in the Thrombocytopenic Cancer Patient

Program: Education Program
Session: Challenges in Cancer-Associated Thrombosis
Hematology Disease Topics & Pathways:
Education
Sunday, December 8, 2024, 4:30 PM-5:45 PM

Cihan Ay

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

Disclosures: Ay: BMS, Pfizer, Daiichi-Sankyo, Bayer, Sanofi, Novo Nordisk, CSL Behring, Sobi, Roche: Honoraria, Speakers Bureau.

See more of: Challenges in Cancer-Associated Thrombosis
See more of: Education Program
<< Previous Presentation | Next Presentation